1.Research Progress in Nano Preparations of Artemisinin and its Derivatives in Anti-tumor Fields
Yang GUAN ; Linyan WANG ; Bingqian HE ; Songwei TAN
China Pharmacist 2017;20(7):1275-1278
Artemisinin and its derivatives have shown the potential application value in anti-tumor fields.But their applications are limited due to poor solubility, short half-life and so on;therefore, many scholars devoted themselves to developing and studying relative pharmaceutical preparations.Nano drug delivery system is a new drug delivery tool.Compared with the traditional dosage forms, such as tablets, suppositories and injections, nano drug delivery system has such advantages as good stability, targeted drug release and combined drug delivery.In this review, nano drug delivery carriers for artemisinin were summarized, including nanoparticles, liposomes, micelles, nanomicroemulsions and so on.The research results and characteristics of artemisinin-containing nano formulas in tumor therapy, as well as the co-delivery system of artemisinin and transferrin, were discussed.
2.Experimental and clinical study on diagnosis of acute intestinal ischemia in early stage
Shiwen WANG ; Jinchun HE ; Ailin SONG ; Linyan WANG
Chinese Journal of General Surgery 2001;0(08):-
ObjectiveTo study the diagnostic value of alteration of serum enzyme in acute intestinal ischemia(AII). MethodsChanges of serum levels of CPK, CKMB, LDH, LA, CRP and CO2CP of venous blood of 40 rabbits and 53 patients in different ischemia conditions at different time before and after operation were measured to determine the relationship between the changes and ischemia degree of intestine. ResultsThe serum levels of CPK, CKMB, LDH, LA and CRP increased gradually with the severity of AII and decreased with the improvement of AII, but CO2CP was the reverse.The 6 assay values mentioned above in animals of AII compared with the control group, and in patients in pretreatment compared with the control group, and in reversible intestinal necrosis compared with irreversible intestinal necrosis, and in nonoperation group 1 h after hospitalization compared with reversible intestinal necrosis group 2 h before operation(except CO2CP)all had remarkable difference(P
3.The clinical efficacy of composite acoustic therapy in patients of sudden deafness with tinnitus.
Zhao LIU ; Yong LIANG ; Chen YANG ; Youli LIU ; Yanfei LI ; Xiaoyan HAN ; Linyan ZENG ; Pingxiang HE
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2015;29(4):330-333
OBJECTIVE:
To determine whether the composite acoustic therapy is effective to treat tinnitus in patients with sudden deafness and to explore the mechanisms.
METHOD:
Ninety-six cases (96 ears) were divided into experimental group and control group, and all the patients underwent drug treatment. The patients in experimental group were given personalized composite acoustic therapy in the first 30 days, music therapy in next 31-90 days, however, the patients in control group were not given sound therapy. Additionally, pure tone audiogram, tinnitus pitch and loudness as well as questionnaires (including THI, VAS, and SAS) were conducted for each patient before treatment, at day 30 and day 90 posttreatment.
RESULT:
Eighty-nine patients (n = 47 for experimental group and n = 42 for control group) completed the trial. The results of day 30 posttreatment showed there were no significant differences in VAS and hearing recovery rate between these two groups, but THI and SAS showed significant differences. The results of day 90 posttreatment showed significant differences in VAS (P < 0.05), THI (P < 0.01) and SAS (P < 0.01), and no significant difference of hearing recovery rate was detected. The most significant changes of VAS appeared in the first 30 days of treatment. The hearing and tinnitus recovery in experimental group were better for the first 30 days of treatment than for the next 31-90 days, and similar results were obtaind in control group. (P < 0.01).
CONCLUSION
Composite acoustic treatment combined with drug therapy can improve the tinnitus and anxiety symptoms of patients with sudden deafness, and the effect on hearing recovery still need to be confirmed in further studies.
Acoustics
;
Anxiety
;
Hearing Loss, Sudden
;
complications
;
therapy
;
Hearing Tests
;
Humans
;
Surveys and Questionnaires
;
Tinnitus
;
complications
;
therapy
;
Treatment Outcome
4. Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex
Shuo DUN ; Liping ZOU ; Mengna ZHANG ; Yangyang WANG ; Wen HE ; Huimin CHEN ; Linyan HU ; Xiaoqiao CHEN ; Qian LU ; Lingyu PANG ; Liying LIU ; Lina TANG ; Bin WANG
Chinese Journal of Pediatrics 2019;57(11):852-856
Objective:
To investigate the efficacy and safety of rapamycin in children with tuberous sclerosis complex (TSC) associated renal disease.
Methods:
A prospective self-control study was conducted. The clinical data of 92 children diagnosed with tuberous sclerosis complex associated kidney disease at the People′s Liberation Army General Hospital from January 2011 to January 2019 were collected. The long-term rapamycin treatment for all patients initiated at 1 mg/(m2·d), which was gradually adjusted to reach a blood concentration of 5-10 μg/L. The changes of the maximum diameter of renal lesions in children after rapamycin treatment were observed and analyzed with Wilcoxon test.
Results:
Ninety-two children, including 52 males and 40 females, who met the criteria were analyzed. Sixty patients had only renal angiomyolipoma(RAML), while 24 patients had only multiple renal cysts(MRC), and 8 patients had both lesions. The age of TSC diagnosis was 16.0 (7.0, 42.0) months, and the age of initial treatment with rapamycin was 63.5 (21.0, 103.0) months. The follow-up lasted for 12.0 (4.0, 23.0) months. Sequencing of TSC1 and TSC2 genes was performed in 54 children with TSC, including 3 patients (6%) with mutations in TSC1 gene and 51 patients (94%) with mutations in TSC2 gene. The maximum RAML diameter before treatment was 7.0 (4.0, 9.0) mm. The best effect reached at 3 months of treatment, with the diameter of 4.0 (0,7.0) mm. The maximum diameters at 6 months, 1 year and 1-2 years were 5.0 (0,9.8) mm, 5.0 (1.5, 8.5) mm, 5.5 (3.0, 9.0) mm, respectively, and were significantly different from the baseline (
5.Coagulation function changes after CD19-CAR-T cells immunotherapy for B-ALL and its related factors
Lan DAI ; Linyan HE ; Ziling ZHU ; Shengli XUE ; Mengjie CAI ; Haixia ZHOU ; Zhaoyue WANG ; Mingqing ZHU
Chinese Journal of Laboratory Medicine 2022;45(8):846-851
Objective:To investigate the changes of various cytokines and coagulation function in B cell acute lymphoblastic leukemia(ALL) patients with different CRS scores during CD19-CAR-T cell immunotherapy.Methods:87 patients with B-ALL hospitalized in the First Affiliated Hospital of Soochow University and 30 normal controls were enrolled into this study from July 2018 to October 2020. The age of the patients was 32(20, 56) years old and 36(41.4%) were female. All these coagulation indicators, prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer, fibrinogen (Fg) were analyzed by automatic blood coagulation in B-ALL patients before and after treated with CAR-T cell. The ratio of CD19-CAR-T cells and the expression of IL-6, IL-10, IFN-γ, TFN-α, IL-2, IL-4, and IL-17A were analyzed using flow cytometry. The patients′ clinical parameters were detected, and the CRS classification of severity was made according to the standard of consensus.Results:Patients with CRS>3 had prolonged PT and APTT, increased D-dimer, and decreased fibrinogen ( P<0.05). The levels of cytokines of IFN-γ, IL-6, and IL-10 were significantly higher in patients with CRS>3 than that in controls ( P<0.05).The D-dimer level is positively correlated with IL-10. Conclusion:Patients with severe CRS grading have significant coagulation dysfunction in CD19-CAR-T cell immunotherapy. Cytokines IFN-γ, IL-6, and IL-10 may affect coagulation function and CRS grading during CD19-CAR-T cell immunotherapy.
6.A multicenter clinical study of the impact of COVID-19 pandemic on hospitalization of children with bronchiolitis
Tianyue WANG ; Yunxiao SHANG ; Lin DONG ; Chuangli HAO ; Meijuan WANG ; Yanqiu ZHANG ; Fei WANG ; Junfeng LIU ; Jun YANG ; Linyan YING ; Chunmei ZHU ; Min LI ; Yinghong FAN ; Heng TANG ; Xiuxiu ZHANG ; Xiaoling WU ; Xiufang WANG ; Zhihong WEN ; Ruiming SHI ; Yun ZHANG ; Min LI ; Zhihui HE ; Rongjun LIN ; Xueyan WANG ; Jun LIU
International Journal of Pediatrics 2023;50(6):397-402
Objective:In order to explore the impact of corona virus disease 2019(COVID-19)on the hospitalization of children with bronchiolitis and to improve clinicians′ understanding of the characteristics of bronchiolitis during the COVID-19 epidemic.Methods:This was a multicenter clinical study, and the data have been collected from 23 children′s medical centers in China.All the clinical data were retrospectively collected from children with bronchiolitis who were hospitalized at each study center from January 1, 2019 to December 31, 2021.The results included gender, age at hospitalization, length of stay, respiratory syncytial virus(RSV) test results, severity rating, ICU treatment, and the total number of children hospitalized with respiratory tract infection during the same period.The clinical data of children with bronchiolitis in 2019 before COVID-19 epidemic and in 2020、2021 during COVID-19 epidemic were statistically analyzed and compared.Results:According to a summary of data provided by 23 children′s medical centers, there were 4 909 cases of bronchiolitis in 2019, 2 654 cases in 2020, and 3 500 cases in 2021.Compared with 2019, the number of bronchiolitis cases decreased by 45.94% in 2020 and 28.70% in 2021.In 2019, 2020 and 2021, there were no significant differences in gender ratio, age, and duration of hospitalization.Compared with 2019, the ratio of bronchiolitis to the total number of hospitalizations for respiratory tract infection decreased significantly in 2020 and 2021( χ2=12.762, P<0.05; χ2=84.845, P<0.05).The proportion of moderate to severe bronchiolitis cases in both 2020 and 2021 was lower than that in 2019, and the difference was statistically significant ( χ2=4.054, P<0.05; χ2=8.109, P<0.05).There was no statistically significant difference in the proportion of bronchiolitis cases requiring ICU treatment between 2019, 2020, and 2021 ( χ2=1.914, P>0.05).In 2019, a total of 52.60%(2 582/4 909) of children with bronchiolitis underwent RSV pathogen testing, and among them, there were 708 cases with RSV positive, accounting for 28.00%.In 2020, 54.14%(1 437/2 654) of children with bronchiolitis underwent RSV pathogen testing, and there were 403 cases with RSV positive, accounting for 28.04%.In 2021, 66.80%(2 238/3 500) of children with bronchiolitis underwent RSV pathogen testing, and there were 935 cases with RSV positive, accounting for 41.78%.Compared with 2019 and 2020, the RSV positive rate in 2021 showed a significant increase( χ2=99.673, P<0.05; χ2=71.292, P<0.05). Conclusion:During the COVID-19 epidemic, the implementation of epidemic prevention and control measures reduced the hospitalization rate and severity of bronchiolitis, but did not reduce the positive rate of RSV detection.
7.Progress in strategies to combat antimicrobial resistance.
Yeshi YIN ; Huahai CHEN ; Linyan CAO ; Lin TANG ; Fulin HE
Chinese Journal of Biotechnology 2018;34(8):1346-1360
Antimicrobial resistance is on the rise while the number of antibiotics being brought to market continues to drop. Drug-resistant genes and drug-resistant bacteria infection have seriously threatened human health. Therefore, antimicrobial resistance presents an ongoing challenge that requires multifaceted approaches including: biomedical innovation; improved surveillance of antibiotic consumption and antimicrobial resistance generated rates; prevention of health-care-associated infections and transmission of multidrug-resistant bacteria and environmental dissemination; rapid microbiological diagnosis; and curtailed clinical and veterinary misuse. Fortunately, combating antimicrobial resistance has been highly valued and supported by the government, scientists and entrepreneurs of various countries. With the continuous introduction of new technologies, new products, and new management measures, the problem of antimicrobial resistance must be controlled and alleviated.